Group 1 Codes Code Description J3590 UNCLASSIFIED BIOLOGICS J9311 INJECTION, RITUXIMAB 10 MG AND HYALURONIDASE J9312 INJECTION, RITUXIMAB, 10 MG Q5115 INJECTION, RITUXIMAB-ABBS, BIOSIMILAR, (TRUXIMA), 10 MG Q5119
Rituximab (Rituxan) HCPCS code J9310 Rituximab, 100 mg, injection: Billing Guidelines. Wednesday, February 7, 2018. Effective with the date of service of April 30, 2018, the North Carolina Medicaid and N.C. Health Choice (NCHC) programs will be terminating Clinical Policy 1B-2, Rituximab (Rituxan), within the Physician Drug Program (PDP).
Providers must bill with HCPCS code: Q5115 - Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg One Medicaid and NC Health Choice unit of coverage is: 10 mg The maximum reimbursement rate per unit is: $91.32 Providers must bill 11-digit NDCs and appropriate NDC units.
Note:For J9311, J9312, J3590 (rituximab-pvvr), Q5115, Q5119 and Q5123. Group 1 Codes Code Description
The RUXIENCE HCPCS code Q5119 is described as “Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg.” Each dose increment of 10 milligrams equals 1 billing unit. For example, a 100 mg vial of RUXIENCE represents 10 billing units of Q5119.
HCPCS code J9312 for Injection, rituximab, 10 mg as maintained by CMS falls under Chemotherapy Drugs.
Rituxan is the trade name for rituximab. In some cases, health care professionals may use the trade name rituxan when referring to the generic drug name rituximab. Drug type: Rituximab is a monoclonal antibody. (For more detail, see "How this drug works" section below).
J3490 or J3590 are approved and valid codes for Bevacizumab when treating neovascular age-related macular degeneration (AMD) by an Ophthalmologist.
Rituximab (Rituxan) HCPCS code J9310 Rituximab, 100 mg, injection: Billing Guidelines.
RITUXAN® (rituximab) is a prescription medicine used to treat: Adults with Non-Hodgkin's Lymphoma (NHL): alone or with other chemotherapy medicines. Adults with Chronic Lymphocytic Leukemia (CLL): with the chemotherapy medicines fludarabine and cyclophosphamide.
Rituxan (rituximab) is a monoclonal antibody medication that treats different types of blood cancer. Rituxan is also an immunotherapy medication, meaning it helps make the immune system better at fighting cancer. Different Rituxan formulations and biosimilars are available.
Rituximab injection is used alone or together with other medicines to treat a type of cancer called non-Hodgkin's lymphoma (NHL). It is also used in combination with other cancer medicines to treat mature B-cell non-Hodgkin's lymphoma (NHL) and mature B-cell acute leukemia (B-AL).
Rituximab is used to treat certain types of cancer (such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia). It works by slowing or stopping the growth of cancer cells. Some brands of rituximab are also used to treat rheumatoid arthritis and can decrease joint pain and swelling.
HCPCS J3490 (unclassified drug) and J3590 (unclassified biologic) are the HCPCS codes that are reported for medications that are biological but have not yet been established, to which the HCPCs code has been assigned.
Meloxicam Injection, for Intravenous Use (Anjeso™) HCPCS Code J3490: Billing Guidelines.
NOC codes are for “Unclassified drugs” or “Not Otherwise Classified” drugs (J3490) and biologics (J3590). Drugs and biologicals appropriately billed using C9399 are separately payable and are priced by Palmetto GBA using Average Wholesale Price (AWP) and CMS pricing methodology.
Effective January 1, 2019 J-code J9312 will replace J9310 for RITUXAN and the billable units will change from 100 mg to 10 mg. Additionally, the permanent J-code assigned for RITUXAN HYCELA is J9311. The RITUXAN AND RITUXAN HYCELA J-Code Flash Card, attached to this email, details the new J-code information.
RITUXAN 500MG 50ML SDV EACHPackage AWP:$5,211.78J-Code:J9312 Injection, rituximab, 10 mgStrength:10 MG/1 MLForm:SolutionNDC Number:50242005306 50242-0053-063 more rows
Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use.
HCPCS code J9035 describes bevacizumab use for chemotherapy, and must not be submitted for intraocular use.
Effective for dates of service 7/1/2021 and after, HCPCS code Q5123 should be used to report rituximab-arrx (Riabni™). For dates of service prior, 12/17/2020 through 6/30/2021, HCPCS code C9399 should be used for Part A and HCPCS code J3590 should be used for Part B to report rituximab-arrx (Riabni™).
Myasthenia gravis, refractory has been added to the “Indications” section of the article. ICD-10-CM codes G70.00 and G70.01 have been added to the “Covered ICD-10 Codes” section effective for dates of service on or after 03/02/2017.
Indications for AIDS-related B-cell lymphomas and Management of immunotherapy related toxicities have been added. ICD-10-CM codes B20, D36.0 and G04.81 have been added effective for dates of service on or after 04/15/2018.